Abstract
Background: M1231 is a bispecific antibody drug conjugate (ADC) targeting tumor-associated mucin 1 (MUC1) and epidermal growth factor receptor (EGFR). Concurrent binding leads to ADC internalization and trafficking to lysosomes where the hemiasterlin-related cytotoxic payload is enzymatically cleaved from the ADC. The released payload interferes with microtubule dynamics and subsequently kills the tumor cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
